LEO Pharma's FDA nod adds a challenger to Dupixent's dominance in eczema - MedCity News
Atopic dermatitis can be difficult for some patients to manage with topical drugs alone. Such cases now have a new FDA-approved treatment option, a biologic drug from LEO Pharma that tackles the chronic inflammatory skin disorder from within the body. The FDA on Tuesday approved LEO drug tralokinumab, the latest in a string of regulatory approvals for the drug this year as a treatment for moderate-to-severe atopic dermatitis, also known as eczema. Ballerup, Denmark-based LEO will market its new drug in the U.S. under the trade name "Adbry." LEO's drug is an antibody designed to bind to and block interleukin-13 (IL-13), a signaling protein called a cytokine that plays a key role in driving atopic dermatitis. Adbry is the first biologic drug approved by the FDA that addresses this disease target. In securing FDA approval, LEO will reach the U.S. market ahead of Eli Lilly, which is pursuing IL-13 with lebrikizumab, an antibody it added via a $1.1 billion acquisition...